StreetAlpha.app
Home › Stocks › OCGN

Ocugen, Inc. (OCGN)

Healthcare
$0.77
▲ +4.79%
LAST CLOSE · NOV 20

Ocugen develops gene therapies aimed at treating inherited retinal diseases and other conditions that cause vision loss. It last closed at $0.77 on Nov 20, up 4.79% on the day. The next earnings report for OCGN is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, OCGN reported EPS of -$0.01 on revenue of $2.0M, with revenue up 11.4% from a year ago. Over its last 8 reports the stock moved an average of 7.4% the session after earnings. Over the last 12 months OCGN insiders bought $26K of stock on the open market and sold $1.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is OCGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OCGN.

Key Stats

Last 12 months
Results
Revenue
$4.8M
−11.0% vs a year ago
Net income
−$65.4M
−1367.3% margin
Free cash flow
−$63.9M
−1336.9% margin
Operating margin
−1444.1%
−$69.0M operating income
Valuation
Market cap
$260.6M
339.3M shares
P/E
–
Price to sales
54.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$24.6M
At Sep 30
Debt
$1.8M
At Sep 30
Shareholder equity
−$17.7M
Shares outstanding
339.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $2.5M$2.5MFY2022FY2023: $6.0M$6.0MFY2023FY2024: $4.1M$4.1MFY2024FY2025: $4.4M$4.4MFY2025

From OCGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · After the close
Reported EPS
-$0.01
Quarter ended Sep 2026
Year ago EPS
-$0.07
Same quarter last year
Revenue
$2.0M
+11.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Mar 2025: -$0.05Mar '25Jun 2025: -$0.05Jun '25Sep 2025: -$0.07Sep '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.07Jun '26Sep 2026: -$0.01Sep '26Latest -$0.01
Revenue by quarter
Dec 2024: $764,000Dec '24Mar 2025: $1.5MMar '25Jun 2025: $1.4MJun '25Sep 2025: $1.8MSep '25Mar 2026: $1.5MMar '26Jun 2026: $1.5MJun '26Sep 2026: $2.0MSep '26Latest $2.0M
How OCGN moved after its last 8 reports
Average move the session after a report ±7.4%
Nov 4, 2026Time not announced+17.4%
Aug 6, 2026Time not announced−3.1%
May 4, 2026After the close−19.5%
Mar 4, 2026After the close−11.2%
Nov 5, 2025Time not announced−1.4%
Aug 1, 2025After the close+0.6%
May 9, 2025Time not announced−2.8%
Mar 5, 2025Time not announced−2.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OCGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OCGN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OCGN

Technical Analysis

OCGN · as of the Nov 20 close · updated each morning
Downtrend

The stock is 5% below its 20 day and 17% below its 50 day average. It is 79% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $0.71, and the nearest resistance the Pivot at $0.77.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$2.7352 week high+254.5%
$1.37200 day average+77.9%
$1.11100 day average+44.2%
$0.9050 day average+16.9%
$0.82Pivot R1+6.5%
$0.8120 day average+5.2%
$0.80Swing high (Oct 28)+3.9%
$0.77Pivot+0.0%
$0.77Last close
$0.71Pivot S1−7.8%
$0.70Swing low (Oct 26)−9.1%
$0.6952 week low−10.4%
Indicators
RSI (14)42.87Middle of its rangeNeutral
MACD-0.03Below its signal lineBearish
Stochastic12.8Near the bottom of its rangeOversold
ADX (14)19.9No clear trend
Williams %R-83.2Oversold below −80, overbought above −20Oversold
CCI (20)-40.6Oversold below −100, overbought above 100Neutral
Rate of change−17.0%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 10.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCGN

What happened before

See how OCGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OCGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OCGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OCGNHow many large options trades hit OCGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OCGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●63 buying vs 57 selling
  • ●Held by funds +0.3 pts
  • ●Funds holding -1
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding147148−0.7%
In funds' top 1000–
Held by funds43.1%42.8%+0.3 pts
New / increased20 / 4343 / 46−29.2%
Reduced / sold out34 / 2326 / 310.0%
Put/call ratio0.770.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OCGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OCGN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$26K1 buy · 1 insider
Sold$1.1M2 sales · 1 insider
100% of the selling was under pre-arranged trading plans.
2026-06 bought $26K2026-09 sold $589K2026-10 sold $500KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 9Shankar MusunuriCEOSale plan525,991$0.95$500K
Sep 9Shankar MusunuriCEOSale plan525,991$1.12$589K
Jun 15Treerita Essalima Johnson-GreeneCFOBuy21,000$1.23$26K
Nov 26, 2024Prabhavathi FernandesDirectorBuy10,000$0.91$9K
Nov 22, 2024Kirsten CastilloDirectorBuy25,000$0.91$23K
Every insider buy and sale for OCGN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OCGN insider trades →

From SEC Form 4 filings by OCGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCGN is in one of them and how their past OCGN trades turned out.

OCGN in the AI portfolios
Loading…

OCGN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OCGN in an article yet. Here's the latest on the wider market.

OCGN in the news

OCGN Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Dec 12
Who traded OCGN · since 2022
Latest 2 filings
$1K – $15KTraded Nov 8, 2022Filed Dec 12, 2022
$15K – $50KTraded Jun 16, 2022Filed Jul 28, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KNov 8, 2022Dec 12, 202234 d
Christopher JacobsR · NYBuy$15K – $50KJun 16, 2022Jul 28, 202242 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Ocugen

Ocugen is a company based in Malvern, Pennsylvania, that develops gene therapies for eye diseases. Its work centers on modifier gene therapies intended to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, an advanced form of macular degeneration. The candidates are designed to be given as a single injection beneath the retina, with the aim of slowing vision loss in patients. The therapies are still in clinical development and are not yet approved for sale.

Headquarters
Malvern, PA